Apr 21, 2017 8:00 am EDT Atara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC)
Apr 20, 2017 4:20 pm EDT Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017
Apr 03, 2017 8:00 am EDT Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer
Mar 17, 2017 12:45 pm EDT Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS)
Mar 09, 2017 8:00 am EST Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights
Jan 03, 2017 8:00 am EST Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD)
Dec 12, 2016 8:00 am EST Atara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, to Support Potential Approval in Two Separate Indications
Dec 03, 2016 10:30 am EST Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016
Nov 04, 2016 8:00 am EDT Atara Bio Announces Third Quarter 2016 Financial Results and Recent Highlights